Xcout IntelSign inSubscribe

OXFORD BIOMEDICA PLC

OXBBiotechOxford, United Kingdom

Oxford Biomedica plc is a biopharmaceutical firm focused on the discovery, advancement, and sophisticated bioprocessing of innovative cell and gene therapies. Operating globally, with a strong presence across Europe, the company organizes its activities into two segments: Platform and Product. Its proprietary LentiVector platform technology facilitates the integration of genes into non-dividing cells, such as neurological cells in the brain and retinal cells in the eye, and can incorporate diverse therapeutic genes. The company's developmental pipeline includes promising candidates like Axo-Lenti-PD, a gene-based treatment for Parkinson's disease. Other pre-clinical stage programs feature OXB-302, targeting haematological tumors, and OXB-401, OXB-40X, and OXB-40Y, all addressing liver indications. Oxford Biomedica maintains numerous strategic alliances with prominent pharmaceutical entities such as Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and the Vaccines Manufacturing and Innovation Centre. Additionally, it engages in research collaborations, including a partnership with Circularis Biotechnologies to identify novel tissue-specific promoters for in vivo lentiviral gene therapy, Virica Biotech for scaling viral medicines, Isolere Bio for enhancing downstream manufacturing efficiencies of biologics, and BiologIC Technologies for utilizing a novel biocomputer system in viral vector development. Founded in 1995, Oxford Biomedica plc is headquartered in Oxford, United Kingdom.

Subscribe to see OXFORD BIOMEDICA PLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

OXFORD BIOMEDICA PLC at a glance

OXFORD BIOMEDICA PLC is a biotech company headquartered in Oxford, United Kingdom, founded in 1996. It is publicly listed (OXB) with a market capitalisation of $808M.

As of 16 November 2026. Source: Xcout Intel.

Industry
Biotech
Headquarters
Oxford, United Kingdom
Market cap
$808M
Employees
986
Ticker
OXB
Founded
1996

OXFORD BIOMEDICA PLC competitors

A few of OXFORD BIOMEDICA PLC's closest competitors — see the full list of competitors and alternatives →

iBio, Inc.IBIO · BiotechSan Diego, CA, United States
64% matchPublic

iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.

Market cap$54.7M
Employees16
iBio, Inc. competitors & alternatives →

Get OXFORD BIOMEDICA PLC's news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Something wrong or missing about OXFORD BIOMEDICA PLC? Suggest a correction · Work at OXFORD BIOMEDICA PLC? Claim this profile

Is this your company? Add the Xcout Intel badge to your website

Free, for any company on Xcout Intel. It links visitors to this profile.

OXFORD BIOMEDICA PLC on Xcout Intel

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

OXFORD BIOMEDICA PLC — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on OXFORD BIOMEDICA PLC in Xcout Intel

  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →